Business Wire·Oct 15, 2025, 8:00 AM ET

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences hired Fish and Richardson P.C. to contest a Post-Grant Review petition filed by Gilgamesh Pharmaceuticals against U.S. Patent No. 12,138,276.
The petition targets claims in the '276 patent that are relevant to Gilgamesh's Bretisilocin molecule, which AbbVie agreed to acquire for up to $1.2 billion on August 25, 2025.
Enveric's lead candidate EB-003 is protected by a separate patent family distinct from the '276 patent family involved in the legal dispute.
The '276 patent family includes one additional issued U.S. patent, pending U.S. applications, 1.2, & international applications in Australia, Canada, China, Europe, Japan, Mexico, & South Korea.
Enveric's total intellectual property portfolio consists of 26 issued U.S. patents & 60 pending national & international applications covering five programs.
The company's pipeline includes EB-003, which targets depression & anxiety via dual 5-HT1B & 5-HT2A receptor agonism & is advancing toward an IND filing.
Enveric also manages the EVM-401 series of small molecules & has out-licensed three programs to third parties with potential milestones totaling up to $205 million plus royalties.
CEO Dr. Joseph Tucker stated the company will vigorously defend its intellectual property & maximize value for shareholders amid major pharmaceutical interest in novel neuropsychiatric solutions.